Novavax's Q4 Update: Good News, Bad News, and Great News
This year has been a whirlwind so far for Novavax (NASDAQ: NVAX). Shares of the biotech have skyrocketed, including a big jump on Tuesday after the Coalition for Epidemic Preparedness (CEPI) awarded Novavax a $4 million grant to develop a vaccine for coronavirus disease COVID-19.
Novavax announced its 2019 fourth-quarter and full-year results after the market closed on Wednesday. The company had some bad news, some good news, and what could be great news.
Image source: Getty Images.
Source Fool.com
